Abstract: With the in-depth study of tumor immune microenvironment, immune checkpoint inhibitors represented by PD-1/PD-L1 inhibitors have achieved promising results in tumor treatment. However, the treatment response rate is low with immunotherapy alone. Integrative therapy is the development trend of tumor therapy. The combined treatment strategies of PD-1/PD-L1 inhibitors with chemotherapy, radiotherapy, TKI, antiangiogenic drugs, etc. are being actively explored. This paper reviews the mechanism and progress of related combined regimens.